<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Myostatin is increased and complexes with amyloid-β within sporadic inclusion-body myositis muscle fibers</title>
			</titleStmt>
			<publicationStmt>
				<publisher>Springer Science and Business Media LLC</publisher>
				<availability status="unknown"><p>Copyright Springer Science and Business Media LLC</p>
				</availability>
				<date type="published" when="2005-06-28">28 June 2005</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Sławomir</forename><surname>Wójcik</surname></persName>
						</author>
						<author>
							<persName><forename type="first">W</forename><forename type="middle">King</forename><surname>Engel</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Janis</forename><surname>Mcferrin</surname></persName>
						</author>
						<author role="corresp">
							<persName><forename type="first">Valerie</forename><surname>Askanas</surname></persName>
							<email>askanas@hsc.usc.edu</email>
						</author>
						<author>
							<affiliation key="aff0">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="institution">USC Neuromuscular Center</orgName>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff1">
								<orgName type="institution">University of Southern California Keck School of Medicine</orgName>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff2">
								<orgName type="institution">Good Samaritan Hospital</orgName>
								<address>
									<addrLine>637 S. Lucas Ave</addrLine>
									<postCode>90017-1912</postCode>
									<settlement>Los Angeles</settlement>
									<region>CA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Myostatin is increased and complexes with amyloid-β within sporadic inclusion-body myositis muscle fibers</title>
					</analytic>
					<monogr>
						<title level="j" type="main">Acta Neuropathologica</title>
						<title level="j" type="abbrev">Acta Neuropathol</title>
						<idno type="ISSN">0001-6322</idno>
						<idno type="eISSN">1432-0533</idno>
						<imprint>
							<publisher>Springer Science and Business Media LLC</publisher>
							<biblScope unit="volume">110</biblScope>
							<biblScope unit="issue">2</biblScope>
							<biblScope unit="page" from="173" to="177"/>
							<date type="published" when="2005-06-28">28 June 2005</date>
						</imprint>
					</monogr>
					<idno type="MD5">89CE885BE6B878F1FE05CA44AD86B4F1</idno>
					<idno type="DOI">10.1007/s00401-005-1035-3</idno>
					<note type="submission">Received: 16 February 2005 / Revised: 18 April 2005 / Accepted: 19 April 2005 /</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2" ident="GROBID" when="2023-03-30T18:12+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p>Myostatin is a negative regulator of muscle mass and strength. Sporadic inclusion-body myositis (s-IBM) is the most common degenerative muscle disease of older persons and is characterized by pronounced muscle wasting. s-IBM is of unknown etiology and pathogenesis, and it lacks definitive treatment. We have now demonstrated in samples from 12 s-IBM biopsies that: (1) by light and electron microscopic immunocytochemistry, myostatin/myostatin precursor is accumulated within muscle fibers and co-localized with amyloid-b (Ab); (2) by immunoblots, both myostatin and myostatin precursor are increased; and (3) by immunoprecipitation, myostatin precursor complexes with Ab. Our study suggests that myostatin/myostatin precursor, either alone, or bound to Ab, may play a novel role in the pathogenesis of s-IBM.</p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p>Myostatin, also called growth and differentiation factor 8 (GDF8), is a member of the transforming growth factor-b (TGF-b) superfamily (reviewed in <ref type="bibr" target="#b3">[4]</ref>). Myostatin is a negative regulator of muscle growth during development and of muscle mass in adulthood <ref type="bibr" target="#b3">[4]</ref>.</p><p>Myostatin has sparked recent interest because a child with a homozygous G fi A transition at nucleotide g.IVS1+5 in the myostatin gene has significantly increased muscle-fiber bulk and is unusually strong <ref type="bibr" target="#b15">[16]</ref>.</p><p>His mother, a heterozygous carrier of the same mutation, is a professional athlete, and others in her family are unusually strong <ref type="bibr" target="#b15">[16]</ref>. This mutation causes missplicing of myostatin mRNA, resulting in reduced production of myostatin protein <ref type="bibr" target="#b9">[10,</ref><ref type="bibr" target="#b15">16]</ref>.</p><p>Conversely, a few previous studies have shown that muscle wasting in patients with HIV is associated with increased myostatin protein in muscle tissue <ref type="bibr" target="#b4">[5]</ref>, and myostatin mRNA is increased in disuse muscle wasting in osteoarthritis <ref type="bibr" target="#b12">[13]</ref>. In mouse models, knocking out the myostatin gene, overexpressing proteins neutralizing myostatin, or natural mutations of the myostatin gene cause larger muscle mass <ref type="bibr" target="#b3">[4,</ref><ref type="bibr" target="#b9">10]</ref>. Naturally occurring myostatin gene mutations cause inactive protein, leading to ''double-muscle'' cattle <ref type="bibr" target="#b10">[11]</ref>, (reviewed in <ref type="bibr" target="#b3">[4,</ref><ref type="bibr" target="#b9">10]</ref>).</p><p>Myostatin has not been previously studied in a human myopathy, to our knowledge. Sporadic inclusionbody myositis (s-IBM), the most common myopathy of persons over the age of 50 years, is of unknown etiology and pathogenesis, and lacks definitive treatment <ref type="bibr" target="#b0">[1]</ref>. It causes progressively severe muscle weakness, wasting and disability <ref type="bibr" target="#b0">[1]</ref>. s-IBM pathology includes: (1) vacuolar degeneration and atrophy of muscle fibers, accompanied by intra-muscle-fiber focal deposits of amyloid-b (Ab), and focal cytoplasmic accumulations of 15-to 21nm-diameter paired-helical filaments (PHFs) containing phosphorylated tau, both accumulations being congophilic; and (2) various degrees of lymphocytic inflammation <ref type="bibr" target="#b0">[1]</ref>. Intriguingly, the s-IBM muscle-fiber molecular morphological phenotype is similar to that of Alzheimer's disease brain, including, in addition to the deposits of Ab and PHF tau, accumulations of several other ''Alzheimer-characteristic'' proteins <ref type="bibr" target="#b0">[1]</ref>.</p><p>We have proposed a key role of increased intracellular Ab in the pathogenesis of s-IBM <ref type="bibr" target="#b0">[1]</ref>, supported by studies showing that experimental overexpression of Ab precursor protein (AbPP) within cultured normal human muscle fibers induced several aspects of the IBM pathological phenotype <ref type="bibr" target="#b1">[2,</ref><ref type="bibr" target="#b8">9]</ref>. Still unknown are the actual mechanisms leading to the multifaceted muscle pathology of s-IBM, including pronounced muscle-fiber atrophy.</p><p>We now ask whether myostatin might contribute to the pathogenesis of muscle weakness and atrophy in s-IBM.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Material and methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Light-microscopic immunocytochemistry</head><p>Immunocytochemistry was performed on 10-lm transverse sections of fresh-frozen diagnostic muscle biopsy specimens obtained, with informed consent, from 34 patients: s-IBM <ref type="bibr" target="#b11">(12)</ref>, dermatomyositis (1), polymyositis (2), oculopharyngeal muscular dystrophy (2), acid maltase deficiency (1), morphologically non-specific myopathy (1), Duchenne muscular dystrophy (3), amyotrophic lateral sclerosis (2), peripheral neuropathy (2) and normal muscle <ref type="bibr" target="#b10">(11)</ref>.</p><p>Single and double immunofluorescence was performed as described <ref type="bibr" target="#b2">[3,</ref><ref type="bibr" target="#b11">12,</ref><ref type="bibr" target="#b17">18,</ref><ref type="bibr" target="#b18">19]</ref>, using a well-characterized anti-myostatin rabbit polyclonal antibody (Chemicon, Temecula, CA), diluted 1:400. This antibody, developed against a myostatin sequence B (NMLYFNGKEQIIYGKI) (Carol Birmingham, Product Manager, Chemicon Laboratories, personal information), recognizes a 28-kDa band of myostatin dimer and 55-kDa band of unprocessed myostatin (myostatin precursor) in human and animal muscle tissue <ref type="bibr" target="#b4">[5,</ref><ref type="bibr" target="#b13">14]</ref>. Two other antibodies against myostatin, from Bethyl Laboratories (Montgomery, TX) and Novus Biologicals (Littleton, CO), were also used, and gave the same results. Ab was identified with mouse monoclonal antibody 6E10 against amino acid residues 1-17 (Signet, Dedham, MA) diluted 1:100, which morphologically recognizes Ab in both Alzheimer's disease brain <ref type="bibr" target="#b6">[7]</ref> and s-IBM muscle <ref type="bibr" target="#b2">[3]</ref>.</p><p>To block nonspecific binding of an antibody to Fc receptors, sections were preincubated with normal goat or donkey serum diluted 1:10 <ref type="bibr" target="#b2">[3,</ref><ref type="bibr" target="#b11">12,</ref><ref type="bibr" target="#b17">18,</ref><ref type="bibr" target="#b18">19]</ref>. Controls for staining specificity were omission of the primary antibody, or its replacement with nonimmune sera or irrelevant antibody; these were always negative.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Immune-electron microscopy</head><p>This was done on 10-lm unfixed frozen sections <ref type="bibr" target="#b2">[3,</ref><ref type="bibr" target="#b11">12,</ref><ref type="bibr" target="#b17">18,</ref><ref type="bibr" target="#b18">19]</ref>. For double immunolocalization, sections were incubated concurrently in a rabbit polyclonal antibody against myostatin combined with the mouse monoclonal antibody 6E10 against Ab, followed by incubation in two different species-specific secondary antibodies conjugated either to 10-or 5-nm gold particles <ref type="bibr" target="#b2">[3,</ref><ref type="bibr" target="#b11">12,</ref><ref type="bibr" target="#b17">18,</ref><ref type="bibr" target="#b18">19]</ref>. The sections were then processed for electron microscopy <ref type="bibr" target="#b2">[3,</ref><ref type="bibr" target="#b11">12,</ref><ref type="bibr" target="#b17">18,</ref><ref type="bibr" target="#b18">19]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Immunoblots</head><p>Immunoblots were performed as described <ref type="bibr" target="#b17">[18,</ref><ref type="bibr" target="#b18">19]</ref>. Briefly, five 20-lm-thick frozen muscle sections were collected at À25°C and rapidly homogenized on ice in 10 mM TRIS-HCl, pH 7.4, containing 150 mM NaCl, 15 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, and protease inhibitor cocktail (Roche Diagnostic, Mannheim, Germany). Protein concentration was measured by the Bradford method. Protein, 20 lg in 4• NuPage LDS sample buffer and 10• NuPage sample reducing agent was heat-denatured for 10 min at 70°C. Subsequently, proteins were electrophoretically separated using 12% Bis-TRIS gel and 1• NuPAGE MES SDS running buffer. After electrophoresis, samples were transferred to a nitrocellulose membrane for 1 h at 30 V, in 1• NuPAGE transfer buffer. All reagents were obtained from Invitrogen (Carlsbad, CA). Nitrocellulose membranes were blocked in 5% (wt/vol) blocking reagent (Amersham Pharmacia Biotech, Piscataway, NJ) in 1• TBS plus 0.1% Tween 20, and they were incubated overnight at 4°C with an anti-myostatin antibody diluted 1:1,000. After being washed, the membrane was incubated with an appropriate species-specific secondary antibody conjugated to horseradish peroxidase. The blots were developed using the enhanced chemiluminescence system (Amersham). Protein loading was evaluated by actin bands visualized with a mouse monoclonal anti-actin antibody (Santa Cruz, CA), diluted 1:1,000. Omission of a primary antibody was the control for reaction specificity. Immunoblots of a recombinant human myostatin peptide (Research Diagnostic, Flanders, NJ ) were used as an additional control for the antibody specificity. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Combined Immunoprecipitation/Immunoblot</head><p>To evaluate whether myostatin physically associates with Ab, a combined immunoprecipitation/immunoblot technique was performed as described <ref type="bibr" target="#b17">[18,</ref><ref type="bibr" target="#b18">19]</ref>: 100 lg total muscle protein from s-IBM and control muscle biopsy specimens were immunoprecipitated in precipitation buffer containing 5 lg 6E10 antibody <ref type="bibr" target="#b17">[18,</ref><ref type="bibr" target="#b18">19]</ref>. The immunoprecipitates were electrophoresed and immunoblotted using an anti-myostatin antibody, followed by a secondary antibody. To confirm the specificity of the immunoprecipitation reaction, either 6E10 antibody was replaced with normal mouse serum, or the antimyostatin antibody used for immunoblotting was omitted.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Light-microscopic immunocytochemistry</head><p>In all s-IBM biopsy samples, on a given cross-section, 70-80% of the vacuolated muscle fibers and approximately 15% of non-vacuolated ones contained, mainly in their non-vacuolated cytoplasm, various-sized dotty, rounded or slightly elongated myostatin-immunoreactive aggregates (Fig. <ref type="figure" target="#fig_0">1</ref>). By double immunofluorescence, all fibers containing myostatin-immunoreactive aggregates also contained Ab-immunoreactive aggregates, and within individual fibers they co-localized with each other (Fig. <ref type="figure" target="#fig_0">1</ref>).</p><p>None of the control diseased or normal biopsy material had muscle fibers containing myostatin-immu-noreactive aggregates. Atrophic muscle fibers in amyotrophic lateral sclerosis and peripheral neuropathy muscle biopsy samples did not have increased myostatin immunoreactivity.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Electron microscopic immunocytochemistry</head><p>Using double-label gold immune electron microscopy, in s-IBM muscle fibers, both myostatin and Ab were associated together with the 6-10 nm amyloid-like fibrils, and floccular and amorphous material (Fig. <ref type="figure" target="#fig_1">2</ref>).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Immunoblots</head><p>Immunoblots of s-IBM muscle biopsy material revealed two very strong bands, one corresponding to a myostatin dimer at 28 kDa, and the other to the myostatin precursor protein at 55 kDa (Fig. <ref type="figure">3</ref>). Control muscle biopsy samples had only very weak bands at 28 and 55 kDa (Fig. <ref type="figure">3</ref>). Omission of a primary antibody resulted in no bands being present (Fig. <ref type="figure">3</ref>). Immunoblots of human recombinant myostatin peptide revealed a very strong 14-kDa myostatin monomer and a weak 28-kDa myostatin dimer (Fig. <ref type="figure">3</ref>).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Immunoprecipitation</head><p>Immunoprecipitation with 6E10 antibody, followed by immunoblotting with anti-myostatin antibody revealed a 55-kDa band corresponding to myostatin precursor protein in s-IBM muscle biopsy specimens, while control muscle did not have a detectable band (Fig. <ref type="figure">3</ref>). Control experiments were negative; details in the legend to Fig. <ref type="figure">3</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p>Our studies demonstrate for the first time that within s-IBM muscle fibers: (1) myostatin/myostatin precursor accumulates and associates with aggregates containing Ab, at both the light and electron microscopic level; (2) expressions of myostatin precursor protein and the myostatin dimer are increased; and (3) myostatin precursor protein physically associates with Ab, identifying Ab as its novel binding partner.</p><p>As in previous studies of human and mouse muscle tissues using the same antibodies <ref type="bibr" target="#b4">[5,</ref><ref type="bibr" target="#b13">14]</ref> and studies of bovine muscle tissue using a different antibody <ref type="bibr" target="#b16">[17]</ref>, we did not detect myostatin monomer in either s-IBM or control muscle biopsy specimens.</p><p>Myostatin is synthesized as a precursor protein, and its monomers form disulfide-linked dimers <ref type="bibr" target="#b3">[4,</ref><ref type="bibr" target="#b5">6,</ref><ref type="bibr" target="#b9">10]</ref>. Processing of myostatin from myostatin precursor protein has been proposed to occur intracellularly, possibly through the action of furin <ref type="bibr" target="#b5">[6]</ref>.</p><p>Myostatin is considered to be a secreted protein <ref type="bibr" target="#b3">[4,</ref><ref type="bibr" target="#b9">10]</ref> that exerts its influence through extracellular signaling induced by autocrine/paracrine action, achieved by its interaction with the activin/TGF-b ActIIb receptor on the muscle fiber <ref type="bibr" target="#b9">[10,</ref><ref type="bibr" target="#b14">15]</ref>. Outside the muscle fiber, myostatin is proposed to be inactivated by its binding to follistatin, which inhibits myostatin binding to its receptors on muscle fibers <ref type="bibr" target="#b3">[4,</ref><ref type="bibr" target="#b9">10]</ref>. The role of myostatin within the muscle fiber and its intracellular binding partners remain to be studied.</p><p>Our data showing increased expression of myostatin and myostatin precursor, and the co-localization and physical association with Ab within s-IBM muscle fibers, suggest that myostatin/myostatin precursor may exert a novel intracellular influence. While we propose that this influence is detrimental, there are several questions. For example, it is not known whether within the s-IBM muscle fibers increased myostatin/myostatin-precursor is detrimental by itself, or it possibly ''toxifies'' intracellular soluble Ab by causing its oligomerization, and possibly it negatively influences other proteins. Also to be considered is whether the binding of Ab to myostatin precursor causes post-translational changes in the latter that might modify its proteolytic processing, degradation and traffic, resulting in increased accumulation of myostatin precursor and myostatin dimer within s-IBM muscle fibers. While those questions remain to be addressed, an immediate practical possibility is that decreasing myostatin/myostatin precursor might be a therapeutic measure in s-IBM. For example, previous treatment with growth hormone significantly decreased myostatin levels in growth hormone-deficient patients and a normal mouse myoblast cell-line <ref type="bibr" target="#b7">[8]</ref>. Accordingly, growth hormone might be considered an anti-myostatin therapeutic candidate for s-IBM. Other possibly therapeutic anti-myostatin compounds can be considered when they become available for human use.</p><p>Fig. <ref type="figure">3</ref> Immunoblots of three s-IBM biopsy homogenates demonstrate a very strong expression of myostatin dimer (28 kDa) and myostatin precursor (55 kDa), while the two normal control (C) muscle biopsy specimens have only very weak bands. The actin band shows the protein loading in each specimen. To confirm the specificity of the antibody, either anti-myostatin antibody was omitted and the blot was reacted with a secondary antibody only, or immunoblotting of the recombinant human myostatin was performed, which revealed two bands (28-kDa dimer, and 14-kDa monomer). Immunoprecipitations of control (lane 3) and s-IBM (lane 4) muscle biopsy tissue with 6E10 antibody against Ab, followed by immunoprobing with the antibody against myostatin, revealed a strong 55-kDa band corresponding to the myostatin precursor in s-IBM muscle (lane 4), while the normal muscle (lane 3) has virtually no band. To confirm the specificity of the immunoprecipitation experiment in s-IBM muscle, either antimyostatin antibody was omitted in the immunoprobing and the blot was reacted with a secondary antibody only (lane 1), or 6E10 antibody was replaced with normal mouse serum (lane 2)-these two controls resulted in the absence of specific bands</p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Fig. 1</head><label>1</label><figDesc>Fig. 1 Immunofluorescence showing myostatin-immunoreactive aggregates in s-IBM abnormal muscle fibers (A, B), and their colocalization with Ab by double immunofluorescence (C-F) (s-IBM sporadic inclusion-body myositis, Ab amyloid-b). Original magnification •1,250</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Fig. 2</head><label>2</label><figDesc>Fig. 2 Single-label (A, B) and double-label (C-E) gold immune electron microscopy within s-IBM muscle fibers. A, B Myostatin is immunolocalized on the inner side of the nuclear membrane in normal (A) and s-IBM (B) muscle fibers. C-E In s-IBM muscle fibers myostatin (5-nm gold particles) and Ab (10-nm gold particles) are associated with 6-10 nm diameter amyloid-like fibrils, and with amorphous and floccular material. A, B •51,000; C •115,000; D •85,000; E •61,000</figDesc></figure>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><p>Acknowledgments This study was supported by grants (to V.A.) from the National Institutes of Health (AG16768 Merit Award), the Myositis Association, the Muscular Dystrophy Association, and the Helen Lewis Research Fund. S.W. is on leave from the Department of Anatomy and Neurobiology, Medical University of Gdansk, Gdansk, Poland. Maggie Baburyan provided excellent technical assistance in electron microscopy.</p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conflict of interest: No information supplied</head></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Proposed pathogenetic cascade of inclusion-body myositis: importance of amyloid-beta, misfolded proteins, predisposing genes, and aging</title>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Opin Rheumatol</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="737" to="744" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Beta APP gene transfer into cultured human muscle induces inclusion-body myositis aspects</title>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Mcferrin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Alvarez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Baque</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuroreport</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="2155" to="2158" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Novel immunolocalization of alpha-synuclein in human muscle of inclusion-body myositis, regenerating and necrotic muscle fibers, and at neuromuscular junctions</title>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Alvarez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Mcferrin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Broccolini</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neuropathol Exp Neurol</title>
		<imprint>
			<biblScope unit="volume">59</biblScope>
			<biblScope unit="page" from="592" to="598" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Role of myostatin in metabolism</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">F</forename><surname>Gonzalez-Cadavid</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Bhasin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Opin Clin Nutr Metab Care</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="451" to="457" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Organization of the human myostatin gene and expression in healthy men and HIV-infected men with muscle wasting</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">F</forename><surname>Gonzalez-Cadavid</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">E</forename><surname>Taylor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Yarasheski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Sinha-Hikim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Ma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ezzat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Shen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Lalani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Asa</forename><forename type="middle">S</forename><surname>Mamita</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Nair</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Arver</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Bhasin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc Natl Acad Sci</title>
		<imprint>
			<biblScope unit="volume">95</biblScope>
			<biblScope unit="page" from="14938" to="14943" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Refolding and purification of unprocessed porcine myostatin expressed in Escherichia coli</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Jin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Dunn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Borthakur</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">S</forename><surname>Kim</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Protein Expr Purif</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="page" from="1" to="10" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Detection and quantitation of amyloid B-peptide with 2 monoclonal antibodies</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">S</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">Y</forename><surname>Wen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Bancher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Sapienza</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Hong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">M</forename><surname>Wisniewski</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurosci Res Commun</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="113" to="122" />
			<date type="published" when="1990">1990</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Myostatin is a skeletal muscle target of growth hormone anabolic action</title>
		<author>
			<persName><forename type="first">W</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">G</forename><surname>Thomas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Asa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Gonzalez-Cadavid</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Bhasin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ezzat</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Endocrinol Metab</title>
		<imprint>
			<biblScope unit="volume">88</biblScope>
			<biblScope unit="page" from="5490" to="5496" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Impaired innervation of cultured human muscle overexpressing bAPP experimentally and genetically: relevance to inclusion-body myopathies</title>
		<author>
			<persName><forename type="first">J</forename><surname>Mcferrin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuroreport</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="3201" to="3205" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Powerful genes-myostatin regulation of human muscle mass</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename><surname>Mcnally</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">350</biblScope>
			<biblScope unit="page" from="2642" to="2644" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Double muscling in cattle due to mutations in the myostatin gene</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Mcpherron</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Lee</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc Natl Acad Sci</title>
		<imprint>
			<biblScope unit="volume">94</biblScope>
			<biblScope unit="page" from="12457" to="12461" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Difference in expression of phosphorylated tau epitopes between sporadic inclusion-body myositis and hereditary inclusion-body myositis</title>
		<author>
			<persName><forename type="first">M</forename><surname>Mirabella</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Alvarez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Bilak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neuropathol Exp Neurol</title>
		<imprint>
			<biblScope unit="volume">55</biblScope>
			<biblScope unit="page" from="774" to="786" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Myostatin, insulin-like growth factor-1, and leukemia inhibitory factor mRNAs are upregulated in chronic human disuse muscle atrophy</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">A</forename><surname>Reardon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Davis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Kapsa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Choong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Byrne</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Muscle Nerve</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="893" to="899" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Lower skeletal muscle mass in male transgenic mice with muscle-specific overexpression of myostatin</title>
		<author>
			<persName><forename type="first">S</forename><surname>Reisz-Porszasz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Bhasin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">N</forename><surname>Artaza</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Shen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Sinha-Hikim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Hogue</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">J</forename><surname>Fielder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">F</forename><surname>Gonzalez-Cadavid</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Physiol Endocrinol Metab</title>
		<imprint>
			<biblScope unit="volume">285</biblScope>
			<biblScope unit="page" from="876" to="888" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Differential response to exogenous and endogenous myostatin in myoblasts suggests that myostatin acts as an autocrine factor in vivo</title>
		<author>
			<persName><forename type="first">R</forename><surname>Rios</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Fernandez-Nocelos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Carneiro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">M</forename><surname>Arce</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Devesa</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Endocrinology</title>
		<imprint>
			<biblScope unit="volume">145</biblScope>
			<biblScope unit="page" from="2795" to="2803" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Myostatin mutation associated with gross muscle hypertrophy in a child</title>
		<author>
			<persName><forename type="first">M</forename><surname>Schuelke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">R</forename><surname>Wagner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">E</forename><surname>Stolz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Hubner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Riebel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Komen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Braun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Tobin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Lee</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">350</biblScope>
			<biblScope unit="page" from="2682" to="2688" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Myostatin, transforming growth factor-b superfamily member, is expressed in heart muscle and is upregulated in cardiomyocytes after infarct</title>
		<author>
			<persName><forename type="first">M</forename><surname>Sharma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Kambadur</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">G</forename><surname>Matthews</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">G</forename><surname>Somers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">P</forename><surname>Devlin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">V</forename><surname>Conglen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Fowke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Bass</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cell Physiol</title>
		<imprint>
			<biblScope unit="volume">180</biblScope>
			<biblScope unit="page" from="1" to="9" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Cystatin C colocalizes with amyloid-beta and coimmunoprecipitates with amyloid-beta precursor protein in sporadic inclusion-body myositis muscles</title>
		<author>
			<persName><forename type="first">G</forename><surname>Vattemi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Mcferrin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neurochem</title>
		<imprint>
			<biblScope unit="volume">85</biblScope>
			<biblScope unit="page" from="1539" to="1546" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Endoplasmic reticulum stress and unfolded protein response in inclusion body myositis muscle</title>
		<author>
			<persName><forename type="first">G</forename><surname>Vattemi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Mcferrin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Pathol</title>
		<imprint>
			<biblScope unit="volume">164</biblScope>
			<biblScope unit="page" from="1" to="7" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
